CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) […]
The post Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Colo-rectal Cancer appeared first on .
Original Article: Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Colo-rectal Cancer